BMS-345541: Selective IKK-1/IKK-2 Inhibitor for NF-κB Pathway Modulation

Executive Summary: BMS-345541 (free base; CAS 445430-58-0) is a small molecule inhibitor that selectively targets IκB kinases IKK-1 and IKK-2, central to NF-κB signaling (BMS-345541 product page). It inhibits IKK-2 with an IC₅₀ of 0.3 μM and IKK-1 with an IC₅₀ of 4 μM under in vitro conditions. BMS-345541 blocks NF-κB-dependent transcription by binding allosterically to IKK enzymes, resulting in suppressed cytokine production and reduced inflammatory signaling (Lv et al., 2020). In cellular and mouse models, it reduces pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-8) and impairs angiogenesis and tumor cell survival. It is an established research tool for modeling inflammatory diseases, apoptosis, and for dissecting the IKK-NF-κB signaling axis (related article).

Biological Rationale

The IKK-NF-κB pathway is a fundamental regulator of inflammation, immune responses, survival, and apoptosis. Dysregulation of this pathway underlies a variety of pathological states, including autoimmune disorders, chronic inflammation, and cancer (Lv et al., 2020). IκB kinases (IKK-1/IKK-2) phosphorylate IκB proteins, targeting them for degradation and releasing NF-κB to translocate to the nucleus. Inhibition of IKKs prevents NF-κB activation, representing a strategic intervention point for experimental and translational research. Selective pharmacological inhibitors such as BMS-345541 enable precise, reversible, and titratable modulation of this pathway, facilitating mechanistic studies and disease modeling (see strategic guidance).

Mechanism of Action of BMS-345541 (free base)

BMS-345541 is a non-ATP-competitive, allosteric inhibitor of IKK-1 and IKK-2 (BMS-345541 details). It binds at a unique allosteric site distinct from the ATP-binding pocket, conferring high selectivity and reducing off-target effects. The compound inhibits IKK-2 with an IC₅₀ of 0.3 μM and IKK-1 with an IC₅₀ of 4 μM in enzyme assays. In cell-based systems, pretreatment with BMS-345541 blocks cytokine-induced phosphorylation of IKK, preventing IκB degradation and subsequent NF-κB nuclear translocation. This results in suppression of NF-κB-dependent genes, including those encoding TNF-α, IL-1β, IL-6, and IL-8. The mechanism has been validated in THP-1 monocytes, glioma, and melanoma cell lines, demonstrating inhibition of proliferation and increased apoptosis in a dose-dependent manner (Lv et al., 2020).

Evidence & Benchmarks

• BMS-345541 inhibits IKK-2 with an IC₅₀ of 0.3 μM and IKK-1 with an IC₅₀ of 4 μM in vitro enzyme assays (ApexBio).
• Pretreatment with BMS-345541 in THP-1 monocytes reduces phosphorylation of IKK, resulting in lower secretion of TNF-α, IL-1β, IL-6, and IL-8 in response to cytokine stimulation (Lv et al., 2020).
• BMS-345541 dose-dependently inhibits LPS-induced serum TNF production in BALB/c mice, with near complete inhibition at 100 mg/kg intraperitoneal administration (ApexBio).
• In glioma and melanoma cell lines, BMS-345541 reduces proliferation and induces apoptosis at concentrations ranging from 1–100 μM, with 1 hour incubation periods (detailed review).
• BMS-345541 suppresses Tβ4-induced angiogenesis and Notch/NF-κB pathway activation in HUVEC and CLI mouse models, demonstrating effective pathway blockade (Lv et al., 2020).

Applications, Limits & Misconceptions

BMS-345541 is widely used for:

• Dissecting cytokine-induced NF-κB activation in inflammation and immune signaling models.
• Evaluating apoptosis induction in cancer cell lines and preclinical tumor models.
• Investigating the role of IKK-NF-κB signaling in angiogenesis, particularly in limb ischemia and vascular remodeling (Lv et al., 2020).
• Serving as a benchmark tool for comparing new IKK inhibitors (see comparative analysis).

Common Pitfalls or Misconceptions

• Non-specific inhibition: BMS-345541 does not broadly inhibit kinases outside of IKK-1/IKK-2 but should not be assumed to block all NF-κB pathway inputs, such as upstream TLR or TNFR signals (ApexBio).
• No direct effect on DNA binding: BMS-345541 does not inhibit NF-κB DNA binding per se; it prevents NF-κB activation by inhibiting IKK-mediated IκB phosphorylation.
• Limited solubility: The compound is insoluble in water and requires DMSO or ethanol (with ultrasonic treatment and warming) for experimental use. Incorrect preparation can lead to precipitation and variable dosing (ApexBio).
• Storage constraints: Solutions of BMS-345541 should not be stored long-term; -20°C storage is recommended for the solid form only.
• Not a clinical therapeutic: BMS-345541 is a research tool and not approved for human therapeutic use.

This article updates and extends the mechanistic details provided in Precision Inhibition of IKK-NF-κB Signaling by offering new evidence from CLI and angiogenesis models.

Workflow Integration & Parameters

Preparation: BMS-345541 is insoluble in water but dissolves at ≥70 mg/mL in DMSO and ≥2.49 mg/mL in ethanol with gentle warming and ultrasonic treatment. For cell-based assays, it is typically used at 1–100 μM with pre-incubation times around 1 hour. For in vivo models, dosing regimens up to 100 mg/kg (i.p.) have been validated for robust IKK inhibition (BMS-345541 protocol).

Storage: Store the solid compound at -20°C; avoid long-term storage of solutions to maintain stability and activity.

Controls and readouts: Experimental design should include appropriate vehicle controls (DMSO/ethanol), time-matched untreated samples, and quantification of NF-κB target gene expression or cytokine secretion as primary readouts. For angiogenesis assays, co-treatment with Notch or NF-κB pathway modulators can distinguish pathway-specific effects (Lv et al., 2020).

Conclusion & Outlook

BMS-345541 (free base) is a validated, selective IKK-1/IKK-2 inhibitor with broad utility in inflammation, cancer, and angiogenesis research. Its allosteric mechanism provides high specificity for NF-κB pathway inhibition, enabling precise dissection of disease-relevant signaling. Limitations include solubility challenges and lack of clinical approval, but its robust performance in preclinical models makes it an indispensable tool for hypothesis-driven research (BMS-345541 B4655 kit). For deeper context, see our strategic guide on leveraging BMS-345541 for translational innovation, which this article updates with new angiogenesis and ischemia data.